It was shown to significantly improve 5-year relative survival rates for patients with chronic-phase CML due to the inhibition of the activation of BCR-ABL by reducing the phosphorylation of the BCR-ABL oncoprotein (Redner, 2010). Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.